CPRX Catalyst Pharmaceuticals, Inc.

+0  (0%)
Previous Close 1.66
Open 1.65
Price To book 3.50
Market Cap 137.73M
Shares 82,972,000
Volume 380,862
Short Ratio 1.39
Av. Daily Volume 1,132,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data met endpoints - March 15, 2017. Pivotal trial planned.
MuSK-antibody positive myasthenia gravis (MuSK-MG)
Phase 3 data due 2H 2017.
Congenital Myasthenic Syndromes (CMS)
Refusal to file letter reported on February 17, 2016. Announced that enrollment had commenced in second Phase 3 trial on December 15, 2016, with data and NDA resubmission due in 2017.
Lambert-Easton Myasthenic Syndrome (LEMS)

Latest News

  1. Catalyst Pharmaceuticals and ZIOPHARM Oncology Bounce Up On FDA Phase News
  2. Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting Stability
  3. Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next
  4. Catalyst reports 4Q loss
  5. Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
  6. Catalyst Pharma Neuromuscular Drug Succeeds In Study
  7. Here’s Why Traders Are Piling Into These Five Stocks
  8. Catalyst Pharma shares jump 22% premarket on news of positive trial results for rare disease
  9. Catalyst Pharma's neuromuscular drug succeeds in study
  10. Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse® in treating MuSK Antibody Positive Myasthenia Gravis
  11. Catalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference
  12. Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Thursday, March 16th, 2017
  13. Catalyst Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases
  14. Catalyst Pharmaceuticals Announces Participation at SunTrust Robinson Humphrey’s 2017 Orphan Drug Day
  15. Harvard Bioscience, Inc. (HBIO): Are Hedge Funds Right About This Stock?
  16. Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma
  17. Catalyst Pharma (CPRX) Q3 Earnings: Will Stock Surprise?